The Online Investor
Daily M&A
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Thu., Apr. 25, 3:25 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #49. Aratana Therapeutics Okapi Sciences NV

Acquirer: Aratana Therapeutics (PETX)
Acquiree: Okapi Sciences NV
Details: Aratana Therapeutics, Inc. (NASDAQ: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today announced that it has acquired Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases. The strategic acquisition of Okapi further enhances Aratana's leadership position in pet therapeutics by bringing with it a unique combination of individuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises.

Aratana Therapeutics is a pet therapeutics company that licenses, develops and commercializes therapeutics for dogs and cats. At Dec 31 2017, Co.'s portfolio included multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and molecule biologics. Co. has three U.S. Food and Drug Administration approved therapeutics: GALLIPRANT® (grapiprant tablets) for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE® (capromorelin oral solution) for appetite stimulation in dogs; and NOCITA® (bupivacaine liposome injectable suspension) as a local post-operative analgesia for cranial cruciate ligament surgery in dogs.

Open the PETX Page at The Online Investor »

Company Name:  Aratana Therapeutics, Inc
Website:  www.aratana.com
Sector:  Drugs & Pharmaceuticals
 

Open the PETX Page at The Online Investor (in a new window) »

April 25, 2024    3:25 AM Eastern
Quotes delayed 20 minutes

Email EnvelopeFree PETX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 49 of 100 | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.